COMPANY PROFILE

GeneMind Biosciences

Explore full profile

High-throughput DNA sequencing instruments and reagents

Shenzhen, ChinaFounded 2012Biotech & Life Sciences

Valuation $250–500M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About GeneMind Biosciences

GeneMind Biosciences (真迈生物) develops high-throughput DNA sequencers and consumables using SURFseq chemistry, including GenoLab M, FASTASeq and SURFSeq platforms with Class III medical-device clearances and multi-country deployments. Founded in 2012 and headquartered in Luohu, Shenzhen, it raised multi-hundred-million RMB C+/D rounds in 2025–2026 for commercialization and global expansion.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2012
Headquarters: Shenzhen, China
Employees: 53
Open positions: 9
Dealroom signal: 49.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Mar 2025	$39M	$571M	Sansure Biotech	↗
SERIES COther financing	Aug 2023	$55M	$220M	Shenzhen Gaoxin Investment · KingMed Diagnostics	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

GeneMind Biosciences website traffic

Latest recorded traffic for GeneMind Biosciences is 4K monthly website visits, up 135.3% over the last three months. GeneMind Biosciences's team grew 6% over the past year.

Latest monthly visits4K 3-month web change+135.3% 1-year team growth+6%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Field Service Engineer518024 Shenzhen, China · Other · Aug 26, 2026 Field Applications Specialist518024 Shenzhen, China · Other · Aug 25, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAscidian TherapeuticsEnables precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time	Boston, United States	Operational	47	$90M	$250M
ATAtalanta TherapeuticsPioneering RNAi treatments for neurodegenerative diseases	Boston, United States	Operational
CTCartesian TherapeuticsCartesian \| Developing potent, safer cell and gene therapies for cancer and autoimmune diseases - Cartesian	Gaithersburg, United States	Operational
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational
ETEpics TherapeuticsDrug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development	Charleroi, Belgium	Operational
LOLocanaCreating a new class of gene therapies by targeting disease-causing messenger RNA	San Diego, United States	Operational
TBTILT BiotherapeuticsTILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments	Helsinki, Finland	Operational
THTheraBiologicsA proprietary human nsc platform for cancer treatment	United States	Operational